University of Montreal, Fernand-Seguin Research Center, Department of Psychiatry, Hochelaga, Montreal, Canada.
Expert Opin Pharmacother. 2010 Dec;11(18):2947-51. doi: 10.1517/14656566.2010.524927. Epub 2010 Oct 28.
Substance use disorders (SUDs) are associated with a variety of psychiatric disorders and mood and behavioral instability. Growing evidence suggests that the atypical antipsychotic quetiapine may be useful in the treatment of SUDs. The primary objective of the current open-label trial was to examine the effects of quetiapine on SUD outcomes in patients entering detoxification.
Thirty-three nonpsychosis SUD patients participated. Patients received quetiapine for a 12-week beginning in detoxification. Craving, quantities used and psychiatric symptoms were evaluated on baseline and at end point.
Out of 33 recruited patients, 26 completed > 9 weeks of treatment. Last observation carried forward (LOCF) analyses revealed that craving, SUD severity and quantities used improved during the study. Psychiatric and depressive symptoms also improved.
Our results cannot be attributed per se to the pharmacological effects of quetiapine owing to the open-label design of the study, the small sample size involved and the fact that patients were involved in an intensive therapy program. Nevertheless, our results indicate that quetiapine may be helpful for the treatment of SUD patients entering detoxification. Controlled studies are warranted to determine whether these results are quetiapine-related.
物质使用障碍（SUD）与各种精神障碍以及情绪和行为不稳定有关。越来越多的证据表明，非典型抗精神病药喹硫平可能对 SUD 的治疗有用。本开放性试验的主要目的是研究喹硫平对进入戒毒期的 SUD 患者的 SUD 结局的影响。
33 名非精神病 SUD 患者参与。患者在戒毒期间开始接受为期 12 周的喹硫平治疗。在基线和终点评估成瘾、使用量和精神症状。
在招募的 33 名患者中，有 26 名完成了 >9 周的治疗。最后一次观察推进（LOCF）分析显示，在研究期间，成瘾、SUD 严重程度和使用量均有所改善。精神病和抑郁症状也有所改善。
由于研究的开放性设计、涉及的小样本量以及患者参与强化治疗计划的事实，我们的结果本身不能归因于喹硫平的药理作用。需要进行对照研究，以确定这些结果是否与喹硫平有关。
